Complicated Intra-Abdominal Infections

Also known as: Complicated Intra-abdominal Infection

DrugDrug NameDrug Description
DB09060AvibactamAvibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens. As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options.
DB01413CefepimeCefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
DB00537CiprofloxacinCiprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
DB06211DoripenemDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.
DB00760MeropenemMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
DB00560TigecyclineTigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
DrugDrug NameTargetType
DB09060AvibactamCanalicular multispecific organic anion transporter 1transporter
DB09060AvibactamSolute carrier family 22 member 8transporter
DB09060AvibactamBeta-lactamase TEMtarget
DB09060AvibactamBeta-lactamase CTX-Mtarget
DB09060AvibactamBeta-lactamase AmpCtarget
DB09060AvibactamBeta-lactamase SHV-1target
DB09060AvibactamBeta-lactamase SHV-2target
DB09060AvibactamBeta-lactamase SHV-1target
DB09060AvibactamClass D OXA-48 carbapenemasetarget
DB09060AvibactamCarbapenem-hydrolyzing beta-lactamase KPCtarget
DB09060AvibactamBeta-lactamase CTX-M-15target
DB09060AvibactamExtended-spectrum beta-lactamase PER-1target
DB01413CefepimeSolute carrier family 22 member 5transporter
DB01413CefepimeSolute carrier family 15 member 1transporter
DB01413CefepimeSolute carrier family 15 member 2transporter
DB01413CefepimePenicillin-binding protein 2target
DB01413CefepimePeptidoglycan synthase FtsItarget
DB01413CefepimePenicillin-binding protein 3target
DB01413CefepimePenicillin-binding protein 2target
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 2-alphatarget
DB00537CiprofloxacinCytochrome P450 1A2enzyme
DB00537CiprofloxacinCytochrome P450 3A4enzyme
DB00537CiprofloxacinCytochrome P450 3A5enzyme
DB00537CiprofloxacinCytochrome P450 3A7enzyme
DB00537CiprofloxacinMultidrug resistance protein 1transporter
DB00537CiprofloxacinPotassium voltage-gated channel subfamily H member 2target
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Atarget
DB00537CiprofloxacinDNA topoisomerase 4 subunit Btarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug resistance protein MdtKtarget
DB00537CiprofloxacinGyrase Atarget
DB00537CiprofloxacinDNA gyrase subunit Atarget
DB00537CiprofloxacinMultidrug and toxin extrusion protein 1transporter
DB00537CiprofloxacinMultidrug and toxin extrusion protein 2transporter
DB00537CiprofloxacinSerum albumincarrier
DB06211DoripenemDipeptidase 1enzyme
DB06211DoripenemPenicillin-binding protein 1Atarget
DB06211DoripenemPenicillin-binding protein 1Btarget
DB06211DoripenemPenicillin-binding protein 2target
DB06211DoripenemPenicillin-binding protein 3target
DB06211DoripenemPenicillin-binding protein 4target
DB06211DoripenemSolute carrier family 22 member 8transporter
DB00760MeropenemD-alanyl-D-alanine carboxypeptidase DacBtarget
DB00760MeropenemBeta-lactamase OXA-10enzyme
DB00560Tigecycline30S ribosomal protein S9target
DB00560Tigecycline16S rRNAtarget
DB00560Tigecycline30S ribosomal protein S14target
DB00560Tigecycline30S ribosomal protein S13target
DB00560Tigecycline30S ribosomal protein S19target
DB00560Tigecycline30S ribosomal protein S12target